About CARBOGEN AMCIS
CARBOGEN AMCIS is a company based in Bubendorf (Switzerland) founded in 1990 was acquired by Dishman Group in August 2006. CARBOGEN AMCIS has raised $4.36 million across 2 funding rounds from investors including HHS, Dishman Group and Solutia. CARBOGEN AMCIS offers products and services including API Manufacturing, Drug Product Development, and Specialities Manufacturing. CARBOGEN AMCIS operates in a competitive market with competitors including Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
- Headquarter Bubendorf, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.36 M (USD)
in 2 rounds
-
Latest Funding Round
$4.36 M (USD), Series A
Sep 02, 2021
-
Investors
HHS
& 2 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CARBOGEN AMCIS
CARBOGEN AMCIS offers a comprehensive portfolio of products and services, including API Manufacturing, Drug Product Development, and Specialities Manufacturing.
Develops and manufactures active pharmaceutical ingredients for clinical use.
Offers formulation and analytical services for sterile drug products.
Produces Vitamin D analogs and cholesterol derivatives under GMP standards.
People of CARBOGEN AMCIS
Unlock access to complete
Software Development Team
41 people
Product Management Team
21 people
Senior Team
20 people
Human Resources and Administration
12 people
Project Team
11 people
Sales and Marketing
11 people
Manager Team
9 people
Head Team
8 people
Unlock access to complete
Funding Insights of CARBOGEN AMCIS
CARBOGEN AMCIS has successfully raised a total of $4.36M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.36 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CARBOGEN AMCIS
CARBOGEN AMCIS has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Dishman Group and Solutia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Additives, functional products, specialty chemicals, and fibers are provided.
|
Locked | Locked | Locked | |
|
CDMO offering its services for the development of APIs and intermediates
|
Locked | Locked | Locked |
Investor details for CARBOGEN AMCIS
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CARBOGEN AMCIS
Investment portfolio details for CARBOGEN AMCIS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CARBOGEN AMCIS
Detailed financials for CARBOGEN AMCIS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Carbogen Amcis Comparisons
Peer comparison for CARBOGEN AMCIS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CARBOGEN AMCIS
CARBOGEN AMCIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| Locked | Locked | Locked |
CDMO focusing on spectrum of dosage forms and therapeutic segments
|
|
| Locked | Locked | Locked |
Pharmaceutical development and manufacturing services are offered contractually.
|
|
| Locked | Locked | Locked |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| Locked | Locked | Locked |
CDMO with a focus on early phase drug product development
|
|
| Locked | Locked | Locked |
Biopharma regulatory affairs, quality control, and strategy services are provided.
|
Detailed competitors of CARBOGEN AMCIS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Carbogen Amcis
Complete news archive for CARBOGEN AMCIS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CARBOGEN AMCIS
CARBOGEN AMCIS was founded in 1990 and raised its 1st funding round 19 years after it was founded.
CARBOGEN AMCIS is headquartered in Bubendorf, Switzerland. It is registered at Bubendorf, Basel-landschaft, Switzerland.
CARBOGEN AMCIS is a funded company, having raised a total of $4.36M across 2 funding rounds to date.
Founded in 1990 and based in Bubendorf, Switzerland, CARBOGEN AMCIS operates as a contract development and manufacturing organization in the pharmaceutical sector. Services encompass chemical process research, API production for preclinical, clinical, and commercial stages, and analytical support including chromatography and parenteral formulations. The company was acquired by Dishman Pharma in 2006 and functions as its subsidiary, focusing on high-potency compounds.
CARBOGEN AMCIS's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
CARBOGEN AMCIS offers API Manufacturing, Drug Product Development, and Specialities Manufacturing.
CARBOGEN AMCIS has 3 investors. Key investors include HHS, Dishman Group, and Solutia.